此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

NG004 in Incomplete Spinal Cord Injury Patients (SPROUT-2)

2026年10月22日 更新者:NovaGo Therapeutics AG

A Randomized, Double-blind, Placebo Controlled Clinical Trial to Investigate the Human Monoclonal Antibody NG004 in Acute, Incomplete Cervical Spinal Cord Injury (SCI) Patients

This is a randomized, double-blind, placebo controlled, multicenter trial of NG004 in patients with acute traumatic incomplete cervical SCI. The trial will evaluate the safety and tolerability, PK, and effects on motor function and daily life functioning of NG004 compared with placebo.

研究概览

研究类型

介入性

注册 (估计的)

120

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

      • Bayreuth、德国
      • Bochum、德国
        • 尚未招聘
        • BG Universitätsklinikum Bergmannsheil
      • Halle、德国
        • 尚未招聘
        • Zentrum für Rückenmarkverletzte und Klinik für Orthopädie, BG Klinikum Bergmannstrost
      • Hamburg、德国
        • 尚未招聘
        • BG Klinikum Hamburg
      • Heidelberg、德国
      • Murnau am Staffelsee、德国
      • Tübingen、德国

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 75年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Acute incomplete cervical SCI (Neurological level of injury C1 ≤ lesion ≤ C8) with confirmed classification of American Spinal Injury Association (ASIA) impairment scale (AIS) B, C and D at Screening
  • 4-28 days post-injury and no earlier than 4 days after spinal surgery
  • No required mechanical ventilation or patients that do not completely depend on mechanical ventilation
  • Hemodynamically and clinical stable patient according to the acute SCI condition at baseline

Exclusion Criteria:

  • Trauma caused by ballistic or other injury that directly penetrates the spinal cord including gunshot and knife wounds
  • Multiple levels of clinically relevant spinal cord lesions
  • Major brachial or lumbar plexus damage/trauma
  • Significant head trauma or other injury that was, in the opinion of the investigator, sufficient to interfere with the assessment of the spinal cord function
  • Other significant pre-existing or current severe systemic disease
  • History of or an episode of multiple sclerosis or Guillain-Barre syndrome
  • History of recent meningitis or meningoencephalitis
  • History of refractory epilepsy
  • Patients with uncontrolled bleeding diathesis and/or who require concomitant therapeutic anticoagulation and not related to SCI
  • Presence of any unstable medical or psychiatric condition
  • Drug dependence any time within the last 6 months before Screening
  • Pregnant or nursing women
  • History of a life-threatening allergic or immune-mediated reaction
  • Presence of infection around the location where the spinal needle insertions are planned for applying the intrathecal injections
  • Participation in any clinical investigation within 4 weeks prior to dosing or longer if required by local regulations
  • Patients who are unconscious

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:四人间

武器和干预

参与者组/臂
干预/治疗
安慰剂比较:安慰剂

repeated intrathecal injections of Placebo within 30 days

实验性的:NG004

repeated intrathecal injections of NG004 within 30 days

研究衡量的是什么?

主要结果指标

结果测量
大体时间
不良事件(AES),严重AE和不良药物反应的类型,频率,严重性和因果关系
大体时间:从治疗开始到6个月
从治疗开始到6个月

次要结果测量

结果测量
措施说明
大体时间
NG004 concentration in serum and CSF
大体时间:From treatment start up to 6 months
From treatment start up to 6 months
Effect on neurological recovery according to the International Standards for the Neurological Classification of Spinal Cord Injury (ISNCSCI) protocol as change in ISNCSCI upper extremities motor score (UEMS) and Integrated Neurological Change Score
大体时间:Baseline to 6 months

The ISNCSCI bilateral Upper Extremity Motor Score (UEMS) is determined by examining the muscle function within each of the 5 myotomes encompassing arm and hand function on each side of the body. A score ranging from 0 to 5 can be given to each myotome tested resulting in a maximum score of 50. Higher values indicate better recovery

Baseline to 6 months
Effect on daily life functioning as Spinal Cord Independence Measure (SCIM-III)
大体时间:Month 6

The SCIM III questionnaire self-care score assesses activities of daily living including feeding, bathing, dressing, and grooming. The self-care score ranges 0-20. The higher scores correspond to better ability to carry out the self-care activities.

Month 6

其他结果措施

结果测量
措施说明
大体时间
Effect on Graded Redefined Assessment of Strength, Sensation and Prehension (GRASSP): strength and prehension performance
大体时间:Month 6

The GRASSP is a validated clinical measure of hand function in tetraplegic patients and can assess changes in impairment over time. The GRASSP (Version 2) consists of 4 subtests. The subtest strength (manual muscle testing of 10 muscles of the upper limb) and the subtest prehension performance (grasping test with 4 activities of daily living) will be performed.

Month 6
Effect on the Walking Index for Spinal Cord Injury (WISCI II)
大体时间:Month 6

WISCI II is a 21-item hierarchical scale of walking based on physical assistance, need of braces and devices, with an ordinal range from 0 (unable to walk) to 20 (walking without assistance for at least 10 meters).

Month 6
Effect on 10-meter walking test (10mWT)
大体时间:Month 6

10mWT is a quantitative measurement of lower extremity function. The patient shall walk a set distance (10 meters) at preferred walking speed. The distance covered, the time taken, and the assistance used will be recorded.

Month 6
Effect on 6-minute walking test (6MWT)
大体时间:Month 6

6MWT is a test used to determine the locomotor performance. Patients are instructed to walk as far as possible during 6 minutes, with rests being taken whenever required. The distance covered in time or until abort, the walking time until abort, and the number of rests are assessed.

Month 6
Effect on respiratory function: Forced Vital Capacity (FVC) and Forced Expiratory volume in one second (FEV1)
大体时间:Baseline up to 6 months

The various lung parameters will include Forced Vital Capacity (FVC), Forced Expiratory volume in one second (FEV1) and peak expiratory flow (PEF).

FVC measures volume in Litter delivered during an expiration made as forcefully and completely as possible starting from full inspiration.

FEV1 assess the volume measured in Litter delivered in the first second of a FVC maneuver. PEF measures highest flow delivered during FVC maneuver (L/min).

Baseline up to 6 months
Effect on respiratory function: Maximal Inspiratory Pressure [MIP] and Maximum Expiratory Pressure [MEP]
大体时间:Baseline up to 6 months

Effect on respiratory function measuring respiratory muscle strength: Maximal Inspiratory Pressure [MIP] and Maximum Expiratory Pressure [MEP]. MIP is assessed as the pressure (in cmH2O) during inhalation against a completely occluded airway and is used to evaluate inspiratory muscle strength. MEP a measure of the strength of expiratory muscles, obtained by having the patient exhale as strongly as possible against a resistance. It is assessed as the pressure (in cmH2O) during exhaling.

Baseline up to 6 months
Effect on spinal cord morphology, lesion size, and tissue integrity using magnetic resonance imaging (MRI) scans
大体时间:Baseline to 6 months

MRI scans of the spine will be used to characterize the extent of the lesion from the SCI by assessing morphological measures. Analyses of lesion parameters as preserved tissue bridges, lesion volume, lesion length, lesion width and spinal cord atrophy will be performed. Spinal cord atrophy is measured by calculating the cross-sectional area (CSA) of the spinal cord. Quantitative MRI will be used to assess microstructural tissue integrity, as assed by diffusion tensor imaging and quantitative magnetization transfer saturation mapping.

Baseline to 6 months
Effect on muscle spasticity (Modified Ashworth Scale [MAS])
大体时间:Month 6

MAS is a 6-point muscle tone assessment scale. Scores range from 0 to 4, where lower scores represent normal muscle tone and higher scores represent spasticity or increased resistance to passive movement.

Month 6
Effect on neuropathic pain (EMSCI Neuropathic Pain Assessment Form [NePAF])
大体时间:Month 6

Neuropathic pain will be assessed by the European Multicenter Study About Spinal Cord Injury (EMSCI) Neuropathic Pain Assessment Form (NePAF), which is based on a structured interview using rating scales, and includes specific assessment of the SCI-associated neuropathic pain in terms of location, quality and severity. The pain intensity is rated with an 11-point numeric rating scale with 0 indicating no pain and 10 indicating the worst imaginable pain.

Month 6

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年8月5日

初级完成 (估计的)

2029年7月1日

研究完成 (估计的)

2029年7月1日

研究注册日期

首次提交

2026年9月7日

首先提交符合 QC 标准的

2026年9月21日

首次发布 (实际的)

2026年9月24日

研究记录更新

最后更新发布 (实际的)

2026年10月23日

上次提交的符合 QC 标准的更新

2026年10月22日

最后验证

2026年10月1日

更多信息

与本研究相关的术语

其他研究编号

  • NG004-SCI-002
  • 2026-526089-26 (EudraCT编号)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅